Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia

• Main Authors: Zhifu Xie (Author), Mei Zhang (Author), Qian Song (Author), Long Cheng (Author), Xinwen Zhang (Author), Gaolei Song (Author), Xinyu Sun (Author), Min Gu (Author), Chendong Zhou (Author), Yangming Zhang (Author), Kexin Zhu (Author), Jianpeng Yin (Author), Xiaoyan Chen (Author), Jingya Li (Author), Fajun Nan (Author)
• Format: Book
• Published: Elsevier, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Hepatic cholesterol accumulation is an important contributor to hypercholesterolemia, which results in atherosclerosis and cardiovascular disease (CVD). ATP-citrate lyase (ACLY) is a key lipogenic enzyme that converts cytosolic citrate derived from tricarboxylic acid cycle (TCA cycle) to acetyl-CoA...